SCHEMBL9997474

SCHEMBL9997474

O=C(O)c1ccc(NS(=O)(=O)Cc2cccc(-c3cc(F)ccc3F)c2)cc1O

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 4/20 0.60
KMT2A Q03164 3/20 0.44
ACLY P53396 3/20 0.43
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HPGD P15428 2/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
FABP4 P15090 3/20 0.40
FABP5 Q01469 2/20 0.40
MCL1 Q07820 1/20 0.39
LTB4R Q15722 1/20 0.39
LTB4R2 Q9NPC1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9997006 0.89 PFKFB3 (0.53) PFKFB3KMT2AACLYMEN1ALDH1A1
SCHEMBL9997264 0.82 PFKFB3 (0.86) PFKFB3KMT2AMEN1ALDH1A1HSD17B10
SCHEMBL9997270 0.79 ACLY (0.58) PFKFB3KMT2AACLYMEN1ALDH1A1
SCHEMBL9997263 0.79 PFKFB3 (0.56) PFKFB3KMT2AMEN1ALDH1A1HSD17B10
SCHEMBL28637116 0.79 ACLY (0.50) PFKFB3KMT2AACLYMEN1ALDH1A1
SCHEMBL15055749 0.78 RORC (0.49) PFKFB3KMT2AMEN1ALDH1A1HPGD
SCHEMBL9997207 0.77 PFKFB3 (0.48) PFKFB3KMT2AACLYMEN1ALDH1A1
SCHEMBL9996898 0.77 ACLY (0.63) PFKFB3KMT2AACLYMEN1ALDH1A1
SCHEMBL15056118 0.75 PFKFB3 (1.00) PFKFB3KMT2AMEN1ALDH1A1HSD17B10
SCHEMBL19288444 0.75 PFKFB3 (0.56) PFKFB3KMT2AMEN1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885KMT2A 1147/4885ACLY 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.